bd2-selective bet inhibitor nuv-868
bd2-selective bet inhibitor nuv-868: sourced relationships with 1 company · 1 clinical trial tracked.
bd2-selective bet inhibitor nuv-868 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could bd2-selective bet inhibitor nuv-868 → NUVB affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Nuvation Bio Inc. (NUVB) | Phase 1 |
Clinical Trial Registry Records (1)
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Primary endpoint: Phase 1 Monotherapy Dose Escalation: Safety and tolerability of NUV-868 to determine the recommended Phase 2 dose (RP2D)
Frequently asked questions
Which companies have sourced relationships with bd2-selective bet inhibitor nuv-868?
bd2-selective bet inhibitor nuv-868 has dated SEC/FDA relationship records for Nuvation Bio Inc..
How many clinical trials involve bd2-selective bet inhibitor nuv-868?
BioSniper tracks 1 clinical trial involving bd2-selective bet inhibitor nuv-868.